| Sector |
Healthcare
|
Compare with Sector peers |
| Industry |
Pharmaceuticals & Drugs
|
Compare with Industry peers |
| Website | http://www.concordbiotech.com | |
| Market Cap | 11,340.92 Cr. | |
| Enterprise Value(EV) | 11,328.71 Cr. | 2023-03 |
| Financial Indicators | ||
|---|---|---|
| Earnings per share (EPS) | 22.95 | Trailing Twelve Months Ending 2023-03 |
| Price-Earning Ratio (PE) | 47.12 | Trailing Twelve Months Ending 2023-03 |
| Industry PE | 38.47 | Trailing Twelve Months Ending 2023-03 |
| Book Value / Share | 275.96 | Trailing Twelve Months Ending 2023-03 |
| Price to Book Value | 3.92 | Calculated using Price: 1,081.25 |
| Dividend Yield | 0.63 | Period Ending 2023-03 |
| No. of Shares Subscribed | 10.46 Cr. | 104,616,204 Shares |
| FaceValue | 1 | |
| About Concord Biotech Ltd. | ||
| The company is an India-based biopharma company and one of the leading global developers and manufacturers of select fermentation-based APIs across Immunosuppressants and oncology. | ||
| 1 Day |
|
+4.16% |
| 1 Week |
|
+11.90% |
| 1 Month |
|
+8.43% |
| 3 Month |
|
|
| 6 Month |
|
|
| 1 Year |
|
|
| 2 Year |
|
|
| 5 Year |
|
|
| 10 Year |
|
| 4 years | 2020-03 | 2021-03 | 2022-03 | 2023-03 | |
| Return on Equity (%) | 21.94 | 26.60 | 16.64 | 20.06 | |
| Return on Capital Employed (%) | 26.23 | 33.01 | 21.66 | 26.70 | |
| Return on Assets (%) | 17.97 | 20.89 | 12.43 | 15.00 |
| Particulars | 4 years | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. |
| Shh. Funds | 770 | 999 | 1,103 | 1,290 | |
| Non Curr. Liab. | 55 | 77 | 54 | 32 | |
| Curr. Liab. | 115 | 236 | 344 | 376 | |
| Minority Int. | |||||
| Equity & Liab. | 941 | 1,313 | 1,502 | 1,699 | |
| Non Curr. Assets | 402 | 706 | 869 | 971 | |
| Curr. Assets | 539 | 607 | 633 | 728 | |
| Misc. Exp. not W/O | |||||
| Total Assets | 941 | 1,313 | 1,502 | 1,699 |
| Particulars | 4 years | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. |
| Net Sales | 512 | 617 | 713 | 853 | |
| Other Income | 31 | 14 | 23 | 35 | |
| Total Income | 544 | 631 | 736 | 888 | |
| Total Expenditure | -308 | -289 | -439 | -505 | |
| PBIDT | 236 | 342 | 297 | 384 | |
| Interest | -1 | -1 | -6 | -10 | |
| Depreciation | -21 | -28 | -50 | -54 | |
| Taxation | -45 | -78 | -63 | -82 | |
| Exceptional Items | |||||
| PAT | 169 | 235 | 175 | 240 | |
| Minority Interest | |||||
| Share Associate | 0 | ||||
| Other Related Items | 0 | ||||
| Consolidated Net Profit | 169 | 235 | 175 | 240 | |
| Adjusted EPS | 16 | 22 | 17 | 23 |
| Particulars | 4 years | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. |
| Cash Fr. Operatn. | 155 | 167 | 207 | 246 | |
| Cash Fr. Inv. | -113 | -195 | -112 | -158 | |
| Cash Fr. Finan. | -43 | 31 | -100 | -85 | |
| Net Change | -1 | 3 | -4 | 3 | |
| Cash & Cash Eqvt | 2 | 5 | 1 | 4 |
|
Fri, 22 Sep 2023
Closure of Trading Window Pursuant to SEBI (Prohibition of Insider Trading) Regulations 2015 as amended from time to time and as per companycode of conduct for regulating monitoring and reporting of trading by insiders the trading window for trading in the equity shares of the company will be closed from October 01 2023 till the expiry of 48 hours after the declaration of the financial results for the Quarter and half year ended september 30 2023. Accordingly all designated persons of the company and their immediate relatives have been advised not to trade in the securities of the company during the aforesaid closure of trading window period. |
|
Wed, 13 Sep 2023
Announcement under Regulation 30 (LODR)-Earnings Call Transcript In continuation of our letter dated September 07 2023 regarding audio recording of Q1FY 24 earning call for investor and anaysts and pursuant to regulation 30(6) of SEBI LODR Please find enclosed transcripts of Q1 FY 24 earning call for the Quarter ended on June 30 2023 |
|
Fri, 08 Sep 2023
Announcement under Regulation 30 (LODR)-Newspaper Publication Pursuant to regulation 47 of SEBI (LODR) regulations 2015 Please find enclosed herewith extracts of the consolidated unaudited financial results for the quarter ended on June 30 2023 as published in the Financial Express all editions and Gujarati language in Ahmedabad editions.Further in terms of regulations 46 of SEBI LODR the said financials results are also uploaded on the website of the company (www.concordbiotech.com) |
| Fri, 29 Sep 2023 |
Close Crossing 52 Week High
|
Closing Above Previous High
|
Closing Above Previous High For 3 Days
|
Making Higher Highs for 3 days
|
Close Within 52 Week High Zone
|
Equities
M.F.
Sectors
StockEdge Social